Biliary Tract Cancer

The addition of durvalumab to standard first-line chemotherapy extended survival among patients with advanced biliary tract cancer, according to topline data released by the agent’s manufacturer.

The FDA granted fast track designation to acelarin for treatment of biliary tract cancer.

The incidence and mortality of gallbladder and biliary tract cancer have increased over the last three decades, according to research published in Cancer.

Ursodeoxycholic acid treatment correlated with reduced mortality, need for liver transplantation and biliary tract cancer in patients with primary sclerosing cholangitis, according to a presenter at The Liver Meeting Digital Experience.

Positive results from a phase 2 study of a three-drug regimen to treat biliary tract cancer paved the way for the first randomized phase 3 study of its kind in the U.S., led by Rachna Shroff, MD, MS.

Henry A. Pitt, MD, has been named chief of oncologic quality at Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital.

The combination of dabrafenib and trametinib appeared active among patients with BRAF V600E-mutated biliary tract cancer, according to results of an ongoing phase 2 basket trial published in The Lancet Oncology.

Atezolizumab plus cobimetinib significantly prolonged PFS compared with atezolizumab alone among a cohort of patients with advanced biliary tract cancer, according to results of a phase 2 study presented at the virtual American Association for Cancer Research Annual Meeting.